SUPERNUS PHARMAC.DL -,001SS

SUPERNUS PHARMAC.DL -,001

31.0EURD
−0.4−1.27%
At close at 21:59 GMT
EUR
No trades
See on Supercharts
Next report date
May 13
Report period
Q1 2025
EPS estimate
0.39 EUR
Revenue estimate
‪137.78 M‬ EUR
Market capitalization
‪1.72 B‬EUR
‪1.19 M‬EUR
‪550.42 M‬EUR
‪52.83 M‬
Beta (1Y)
0.92
Employees (FY)
652
Change (1Y)
+40 +6.54%
Revenue / Employee (1Y)
Net income / Employee (1Y)

About Supernus Pharmaceuticals, Inc.


CEO
Jack A. Khattar
Headquarters
Rockville
Founded
2005
FIGI
BBG004DSBQW0
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Performance
‪−11%‬
‪0%‬
‪11%‬
‪22%‬
‪33%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−60.00 M‬‬
‪0.00‬
‪‪60.00 M‬‬
‪‪120.00 M‬‬
‪‪180.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪40.00 M‬‬
‪‪80.00 M‬‬
‪‪120.00 M‬‬
‪‪160.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪40.00 M‬‬
‪‪80.00 M‬‬
‪‪120.00 M‬‬
‪‪160.00 M‬‬
Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪25.00 M‬‬
‪‪50.00 M‬‬
‪‪75.00 M‬‬
‪‪100.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Earnings
Next:May 13, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪0.30‬
‪0.60‬
‪0.90‬
‪1.20‬
Actual
Estimate

No news here

Looks like there's nothing to report right now

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange SUPERNUS PHARMAC.DL -,001 stocks are traded under the ticker S49.
We've gathered analysts' opinions on SUPERNUS PHARMAC.DL -,001 future price: according to them, S49 price has a max estimate of 41.94 EUR and a min estimate of 34.31 EUR. Watch S49 chart and read a more detailed SUPERNUS PHARMAC.DL -,001 stock forecast: see what analysts think of SUPERNUS PHARMAC.DL -,001 and suggest that you do with its stocks.
S49 reached its all-time high on Jun 29, 2018 with the price of 52.0 EUR, and its all-time low was 3.4 EUR and was reached on Apr 25, 2013. View more price dynamics on S49 chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track SUPERNUS PHARMAC.DL -,001 financials in yearly and quarterly reports right on TradingView.
SUPERNUS PHARMAC.DL -,001 is going to release the next earnings report on May 13, 2025. Keep track of upcoming events with our Earnings Calendar.
S49 earnings for the last quarter are 0.72 EUR per share, whereas the estimation was 0.50 EUR resulting in a 43.54% surprise. The estimated earnings for the next quarter are 0.39 EUR per share. See more details about SUPERNUS PHARMAC.DL -,001 earnings.
SUPERNUS PHARMAC.DL -,001 revenue for the last quarter amounts to ‪168.23 M‬ EUR, despite the estimated figure of ‪149.97 M‬ EUR. In the next quarter, revenue is expected to reach ‪137.78 M‬ EUR.
S49 net income for the last quarter is ‪34.58 M‬ EUR, while the quarter before that showed ‪18.59 M‬ EUR of net income which accounts for 85.95% change. Track more SUPERNUS PHARMAC.DL -,001 financial stats to get the full picture.
No, S49 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 25, 2025, the company has 652.00 employees. See our rating of the largest employees — is SUPERNUS PHARMAC.DL -,001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SUPERNUS PHARMAC.DL -,001 EBITDA is ‪140.11 M‬ EUR, and current EBITDA margin is 16.17%. See more stats in SUPERNUS PHARMAC.DL -,001 financial statements.
Like other stocks, S49 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SUPERNUS PHARMAC.DL -,001 stock right from TradingView charts — choose your broker and connect to your account.